Salix Pharmaceuticals Ltd (SLXP)

172.81
0.16 0.09
NASDAQ : Health Care
Prev Close 172.65
Open 172.72
Day Low/High 172.71 / 172.96
52 Wk Low/High 86.00 / 172.98
Volume 4.30M
Avg Volume 3.38M
Exchange NASDAQ
Shares Outstanding 64.25M
Market Cap 11.10B
EPS -6.53
P/E Ratio N/A
Div & Yield N.A. (N.A)
Salix Reaches New 52-Week High (SLXP)

Salix Reaches New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Tuesday as it is currently trading at $54.53, above its previous 52-week high of $53.99 with 24,681 shares traded as of 9:40 a.m. ET. Average volume has been 756,600 shares over the past 30 days.

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals To Present At Three Investment Conferences In June

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at three investment conferences during June 2012.

Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2012

Salix Pharmaceuticals Outlines Data Presentations At Digestive Disease Week 2012

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that numerous presentations and educational activities related to the investigation of several of the Company’s products or relevant disease states are ...

Strength in Adversity

Strength in Adversity

If you're a buyer, look at these names as opposed to some of the go-to stocks of the past year.

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Winner

Salix Pharmaceuticals Ltd. (SLXP): Today's Featured Health Care Winner

Salix Pharmaceuticals was a winner within the health care sector, rising $2.52 (5.1%) to $52.12 on heavy volume.

Salix Pharmaceuticals Reports 1Q2012 Results

Salix Pharmaceuticals Reports 1Q2012 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the first quarter ended March 31, 2012 and other business updates.

Salix Pharmaceuticals Announces Extension Of Crofelemer NDA Priority Review

Salix Pharmaceuticals Announces Extension Of Crofelemer NDA Priority Review

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the U.

Salix And Progenics Announce FDA Extension Of RELISTOR® SNDA Goal Date To July 27, 2012

Salix And Progenics Announce FDA Extension Of RELISTOR® SNDA Goal Date To July 27, 2012

Salix Pharmaceuticals, Ltd. (NASDAQ: SLXP) and Progenics Pharmaceuticals (NASDAQ: PGNX) today announced that the Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) goal date for...

Salix Pharmaceuticals Announces 1Q2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 1Q2012 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report first quarter 2012 financial results following the close of the U.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Monday as it is currently trading at $53.75, above its previous 52-week high of $53.58 with 129,895 shares traded as of 10:20 a.m. ET. Average volume has been 943,200 shares over the past 30 days.

Salix Pharmaceuticals Closes Sale Of Convertible Notes

Salix Pharmaceuticals Closes Sale Of Convertible Notes

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the closing of its offering of $690 million aggregate principal amount of 1.

Salix Reaches New 52-Week High (SLXP)

Salix Reaches New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Thursday as it is currently trading at $51.95, above its previous 52-week high of $51.42 with 1.1 million shares traded as of 3:55 p.m. ET. Average volume has been 943,200 shares over the past 30 days.

Financials Guiding Market Direction

Their price action should be more instructive, and laggards could play catch up if those issues stay firm.

Salix Rises On Unusually High Volume (SLXP)

Salix Rises On Unusually High Volume (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) is trading at unusually high volume Tuesday with 3.9 million shares changing hands. It is currently at 4.2 times its average daily volume and trading up $1.76 (+3.6%).

Salix Pharmaceuticals Prices Convertible Notes Offering

Salix Pharmaceuticals Prices Convertible Notes Offering

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the pricing of its offering of $600 million aggregate principal amount of 1.

Beating Inflation With Biotech

Biotech and pharma companies have the biggest edge in pricing power.

Salix Pharmaceuticals Announces Proposed Convertible Notes Offering

Salix Pharmaceuticals Announces Proposed Convertible Notes Offering

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced its intention to offer, subject to market and other customary conditions, $500 million aggregate principal amount of convertible senior notes due 2019 to ...

Seasonal Bias Shifts Negative

The first of the month positive bias ends today, so there's no guarantee of a higher close into the weekend.

5 Stocks Poised for Breakouts

5 Stocks Poised for Breakouts

These stocks are setting up to break out and trade higher from current levels.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Tuesday as it is currently trading at $50.34, above its previous 52-week high of $50.28 with one million shares traded as of 11:10 a.m. ET. Average volume has been 943,200 shares over the past 30 days.

Salix Pharmaceuticals To Present At Cowen Health Care Conference

Salix Pharmaceuticals To Present At Cowen Health Care Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Cowen and Company 32 nd Annual Health Care Conference in Boston, MA on Tuesday, March 6, 2012 at 10:40 a.

Salix Pharmaceuticals Reports 4Q And FY2011 Results

Salix Pharmaceuticals Reports 4Q And FY2011 Results

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced financial and operating results for the fourth quarter and full year ended December 31, 2011 and other business updates.

Salix Pharmaceuticals Announces Initiation Of Target 3: A Phase 3 Study To Assess Repeat Treatment Efficacy And Safety Of Rifaximin 550MG TID In Subjects With Irritable Bowel Syndrome With Diarrhea

Salix Pharmaceuticals Announces Initiation Of Target 3: A Phase 3 Study To Assess Repeat Treatment Efficacy And Safety Of Rifaximin 550MG TID In Subjects With Irritable Bowel Syndrome With Diarrhea

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the initiation of TARGET 3 - a Phase 3 study to evaluate the efficacy and safety of repeat treatment with rifaximin 550 mg TID (three times daily) for 14 days...

Salix Pharmaceuticals To Present At RBC Capital Markets Healthcare Conference

Salix Pharmaceuticals To Present At RBC Capital Markets Healthcare Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the 2012 RBC Capital Markets Healthcare Conference in New York, NY on Tuesday, February 28, 2012 at 2:35 p.

Salix Pharmaceuticals Announces 4Q2011 And FY2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals Announces 4Q2011 And FY2011 Financial Results Conference Call And Webcast

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will report fourth quarter and full year 2011 financial results following the close of the U.

These, at Least, Are Gaining Steam

These, at Least, Are Gaining Steam

Amid a timid rally, I see potential breakouts for these names -- though better broad action would help.

Salix Stock Hits New 52-Week High (SLXP)

Salix Stock Hits New 52-Week High (SLXP)

Salix Pharmaceuticals (Nasdaq:SLXP) hit a new 52-week high Tuesday as it is currently trading at $49.47, above its previous 52-week high of $49.07 with 45,771 shares traded as of 10:05 a.m. ET. Average volume has been 940,300 shares over the past 30 days.

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Salix Pharmaceuticals To Present At J.P. Morgan Healthcare Conference

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at The 30 th Annual J.

An Upbeat Outlook for 2012

I see a new bull market by March, a stronger euro, and lots of M&A activity in the coming year.